Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 31;20(1):2432745.
doi: 10.1080/21645515.2024.2432745. Epub 2024 Dec 9.

Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged ≥60 years in the United States

Elizabeth M La  1 , Jonathan Graham  2 , David Singer  1 , Daniel Molnar  3 , Sara Poston  1 , Desmond Curran  3 , Jessica Pickett  1 , Frederik Verelst  3
Affiliations

Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged ≥60 years in the United States

Elizabeth M La et al. Hum Vaccin Immunother. .

Abstract

Respiratory syncytial virus (RSV) is a common cause of acute respiratory illness in individuals of all ages, with adults aged ≥60 years and adults with certain chronic conditions at increased risk of severe RSV-related outcomes. This study evaluates the cost-effectiveness of the adjuvanted RSVPreF3 vaccine versus no vaccine in adults aged ≥60 years in the United States (US). A multi-cohort Markov model was developed with a 5-year time horizon and 1-month cycle length to compare outcomes for no vaccination and one-time adjuvanted RSVPreF3 vaccination (assuming the same vaccination as for influenza vaccines). Clinical parameters (e.g., vaccine efficacy) were based on phase 3 clinical trial data over 3 seasons, with all other inputs obtained from public US sources and scientific literature. Outcomes included total and incremental quality-adjusted life year (QALY) losses and costs, as well as incremental cost-effectiveness ratios (ICERs). Sensitivity analyses were conducted to evaluate the sensitivity of results to inputs. In the base case, the model estimated that vaccinating 52.7 million adults aged ≥60 years with the adjuvanted RSVPreF3 vaccine once would result in 244,424 fewer QALY losses and an incremental societal cost of $4.5 billion over 5 years, with vaccination costs partially offset by reduced disease-related costs. From the societal perspective, adjuvanted RSVPreF3 vaccination resulted in an ICER of $18,430 per QALY gained. Results were relatively robust across sensitivity analyses and indicate that adjuvanted RSVPreF3 vaccination is a cost-effective option for the prevention of RSV in US adults aged ≥ 60 years, reducing the substantial burden within this population.

Keywords: Respiratory syncytial virus; United States; adjuvanted RSVPreF3 vaccine; cost-effectiveness; older adults; vaccination.

PubMed Disclaimer

Conflict of interest statement

Elizabeth La, David Singer, Sara Poston, Desmond Curran, Jessica Pickett, and Frederik Verelst are employed by and hold financial equities in GSK. Daniel Molnar was employed by GSK at the time of the study. Jonathan Graham is employed by RTI Health Solutions, which received funding from GSK for the conduct of this study. All authors declare no other financial or non-financial relationships and activities.

Figures

Figure 1.
Figure 1.
Markov model structure.
Figure 2.
Figure 2.
Adjuvanted RSVPreF3 vaccine efficacy against RSV-ARI and RSV-LRTD over modeled 5-year time horizon.
Figure 3.
Figure 3.
Deterministic sensitivity analysis results for the cost-effectiveness of adjuvanted RSVPreF3 vaccine versus no vaccine for US adults aged ≥60 years over a 5-year period.
Figure 4.
Figure 4.
Probabilistic sensitivity analysis results for the cost-effectiveness of adjuvanted RSVPreF3 vaccine versus no vaccine for US adults aged ≥60 years over a 5-year period.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Walsh EE. Respiratory syncytial virus infection: an illness for all ages. Clin Chest Med. 2017;38(1):29–12. doi:10.1016/j.ccm.2016.11.010. - DOI - PMC - PubMed
    1. Coultas JA, Smyth R, Openshaw PJ. Respiratory syncytial virus (RSV): a scourge from infancy to old age. Thorax. 2019;74(10):986–993. doi:10.1136/thoraxjnl-2018-212212. - DOI - PubMed
    1. Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging. 2015;32(4):261–269. doi:10.1007/s40266-015-0258-9. - DOI - PubMed
    1. Belongia EA, King JP, Kieke BA, Pluta J, Al-Hilli A, Meece JK, Shinde V. Clinical features, severity, and incidence of RSV illness during 12 consecutive seasons in a community cohort of adults ≥60 years old. Open Forum Infect Dis. 2018;5(12):ofy316. doi:10.1093/ofid/ofy316. - DOI - PMC - PubMed
    1. McLaughlin JM, Khan F, Begier E, Swerdlow DL, Jodar L, Falsey AR. Rates of medically attended RSV among US adults: a systematic review and meta-analysis. Open Forum Infect Dis. 2022;9(7):ofac300. doi:10.1093/ofid/ofac300. - DOI - PMC - PubMed

MeSH terms

Substances